Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History KROS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics KROS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Keros Therapeutics Inc

KROS
Current price
13.40 USD 0 USD (0.00%)
Last closed 13.45 USD
ISIN US4923271013
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 546 277 120 USD
Yield for 12 month -67.85 %
1Y
3Y
5Y
10Y
15Y
KROS
21.11.2021 - 28.11.2021

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Address: 1050 Waltham Street, Lexington, MA, United States, 02421

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

29.20 USD

P/E Ratio

Dividend Yield

Financials KROS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures KROS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+3 550 000 USD

Last Year

+151 000 USD

Current Quarter

+211 246 000 USD

Last Quarter

+3 042 000 USD

Current Year

+2 321 000 USD

Last Year

-664 000 USD

Current Quarter

+211 246 000 USD

Last Quarter

+2 710 000 USD
EBITDA -9 014 000 USD
Operating Margin TTM 71.97 %
Price to Earnings
Return On Assets TTM -1.01 %
PEG Ratio
Return On Equity TTM 0.71 %
Wall Street Target Price 29.20 USD
Revenue TTM 214 712 992 USD
Book Value 17.97 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 254 413.30 %
Dividend Yield
Gross Profit TTM 204 262 000 USD
Earnings per share -0.17 USD
Diluted Eps TTM -0.17 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin 1.96 %

Stock Valuation KROS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 48.78
Enterprise Value Revenue 6 490.26
Price Sales TTM 2.54
Enterprise Value EBITDA -13.05
Price Book MRQ 0.75

Technical Indicators KROS

For 52 Weeks

9.12 USD 72.37 USD
50 Day MA 14.03 USD
Shares Short Prior Month 5 306 156
200 Day MA 27.59 USD
Short Ratio 6.79
Shares Short 4 702 282
Short Percent 18.14 %